Allarity announces Trial-in-Progress poster for Phase 2 stenoparib at ESMO Gynaecological Cancers Congress 2026

Allarity Therapeutics, Inc.

Poster outlines Phase 2 trial of stenoparib (dual PARP/WNT inhibitor) for platinum-resistant ovarian cancer.
Presented by Principal Investigator Dr. Kathleen N. Moore, expert in advanced ovarian cancer.
No new clinical data reported; Trial-in-Progress design describes study rationale and design only.
Conference held June 17–19, 2026 in Copenhagen, Denmark; poster displayed June 18, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.